基于FDA不良事件报告系统 (FAERS) 进行的netarsudil的现实世界药监测研究
Xiaomei Xiong1, Xiuwen Zhang1, Fengmin Tang1
1Department of Pharmacy, Eye & ENT Hospital, Fudan University, No.83 Fenyang Rd, Shanghai, 200031, China.
BMC pharmacology & toxicology
|April 21, 2025
概括
这项研究使用FDA数据确定了netarsudil的新型眼部和全身副作用. 大多数netarsudil不良事件 (AEs) 发生在服用后不久,突出了早期监测的必要性.
科学领域:
- 药物监督 药物监督 药物监督
- 眼科医生 眼科 眼科
- 药品安全 药品安全
背景情况:
- 尼塔苏迪尔的安全数据主要来自临床试验.
- 这项研究使用FDA不良事件报告系统 (FAERS) 调查眼睛和系统安全性.
研究的目的:
- 识别和描述与netarsudil相关的眼部和全身不良事件 (AE) 信号.
- 通过数据挖掘探索netarsudil的安全概况.
主要方法:
- 从FAERS (2018年1月至2024年9月) 提取了AE报告.
- 使用报告几率比率 (ROR) 来检测与netarsudil相关的AE信号.
- 进行了子组,开始时间 (TTO) 和敏感性分析,以进行全面的安全评估.
主要成果:
- 确定了63个AE信号,包括38个已知的眼部AE信号 (例如,结膜性高血症) 和21个新的眼部AE信号 (例如,过敏白炎).
- 发现了4个意想不到的全身AE信号 (例如,过敏,面部胀).
- 发现的副作用主要发生在第一个月内,中位数TTO为1天;老年患者 (≥65) 显示炎症相关的副作用增加.
结论:
- 这项药监测研究确定了netarsudil的新型眼部和全身不良事件信号.
- 与内塔苏迪尔相关的副作用通常在服用后很早出现,因此需要保持警的临床监测和风险管理策略.
相关概念视频
01:19Pharmacovigilance
739
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
739
01:25Drug Regulation
1.2K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.2K
01:11Clinical Trials: Overview
2.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.4K
01:17Drug Nomenclature
1.5K
During the development of a new pharmaceutical, the manufacturer initially assigns a code name to the drug. Once approved, the drug receives a United States Adopted Name (USAN)—a generic, nonproprietary designation. Upon being listed in the United States Pharmacopeia, this nonproprietary name becomes the drug's official name. Additionally, the manufacturer assigns a proprietary name or trademark, which serves as the brand name under which the drug is marketed. It is worth noting that...
1.5K